T 0835/21 (LRP6 antibodies/BOEHRINGER INGELHEIM) of 28.03.2023
- European Case Law Identifier
- ECLI:EP:BA:2023:T083521.20230328
- Date of decision
- 28 March 2023
- Case number
- T 0835/21
- Petition for review of
- -
- Application number
- 12188230.2
- IPC class
- C07K 16/28A61P 35/00A61K 39/395
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6)
- Applicant name
- Novartis AG
- Opponent name
- Boehringer Ingelheim RCV GmbH & Co KG /
Boehringer Ingelheim International GmbH (opposition withdrawn)
Merck Patent GmbH - Board
- 3.3.08
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2)European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 76(1)European Patent Convention Art 83
- Keywords
- Novelty - (yes)
Inventive step - could-would approach
Sufficiency of disclosure - reproducibility (yes)
Divisional application - added subject-matter (no)
Amendments - allowable (yes) - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the order to maintain the patent with claims 1 to 9 of the main request, filed as auxiliary request 1 with the reply to the appeal, and a description possibly to be adapted thereto.